The teams from the Institute attending the WMS conference

Thursday 1 October 2026 

➢ Topic 2: Drug-induced myopathies – Moderators: Yves Allenbach and Wen-Chen Liang, 

• 09O – Drug-induced myopathies: a pharmacovigilance-based study of the spectrum of drug toxicity, with a focus on anticancer agents – Mohamed-Yacine Khitri, Paul Gougis, Kevin Bihan, Bénédicte Lebrun-Vignes, Julian Sanchez-Dal Cin, Yves Allenbach 
• 10O – Defining the Histopathologic Spectrum of ICI-Related Myositis: Toward Validation of a Standardized Diagnostic Score – Beatrice Labella, Sami Tayb-boulahfa, Teresinha Evangelista, Hortense Chassepot, Yves Allenbach, Sarah Leonard-louis

➢ Short Oral Presentations 2: Toxic and inflammatory myopathies 

• SP09 – Immune checkpoint inhibitor–related myotoxicity: clinical spectrum, predi- ctors of severity, and development of a pragmatic prognostic score – Sami Tayb-Boulahfa, Lucas Pacoureau, Marie-Claire Bretagne, Sarah Léonard-Louis, Beatrice Labell, Eric Ballot, Marie-Alexandra Alyanakian, Rana Al Kouri, Olivier Benveniste, Joe-Elie Salem, Yves Allenbach

➢ Poster Sessions

• 2.07eP – Baseline data from pediatric patients with LAMA2 related dystrophies enrolled in a prospective and longitudinal natural history study in France – Marjorie Banos, Erwan Gasnier, Abdennour Chellah, Melina Brindeau, Aurelie Phelep, Dominique Duchene, Frederic Fer, Marta Gomez Garcia de la Banda, Pierre Dupont, Soraya Houmel, Carole Vuillerot, Shotaro Tachibana, Sabrina Oumnia, Ulrike Walther-Louvier, Souad Touati, Lea Thevenet, Saadane Kirouani, Susana Quijano Roy, Andreea Seferian
• 2.14P – In vitro« Dans le verre », expériences réalisées en laboratoire en dehors de l’organisme. characterization of the extracellular matrix and basement membrane in LAMA2-related congenital muscular dystrophies – Louise Benarroch, Lauren Struble, Kamel Mamchaoui, Anne Bigot, Nur Villar-Quiles, Tanya Strojkovic, Valérie Allamand
• 1.08P – Clinical trial readiness for LGMDR1: 12 months results from the CALNATHIS prospective study identify clinically meaningful readouts – Gianmarco Severa, Christophe Alimi, Tanya Stojkovic, Céline Tard, Jean Baptiste Noury, Stéphane Degove, Sarah Souvannanorath, Sophie Olivier, Isabelle Richard, Edoardo Malfatti
• 1.58eP – Accelerating ALS trials through muscle-centered assessment – Jean-yves Hogrel, Ghida Trad, Timothée Lenglet, Isabelle Ledoux, Giorgia Querin, Véronique Marchand-Pauvert, Pierre-François Pradat
• 1.55P – Multi-domain response analysis of adult spinal muscular atrophy patients treated with risdiplam: insights from a real-world two-center French study – Claire Lefeuvre, Jean-Yves Hogrel, Frederic Fer, Marion Masingue, Marjorie Banos, Edouard Berling, Anthony Behin, Sarah Leonard- Louis, Guillaume Bassez, Gorka Fernandez, Alice Rouyer, Clement Guemy, Noemie Petit, Fanny Chantreuil, Sylvain Petit, Guillaume Nicolas, Pascal Laforet, Tanya Stojkovic, Tanya Stojkovic 
• 2.73eP – Leveraging patient-derived myoblasts and FAPs to study neuromuscular diseases – Anne Bigot, Kamel Mamchaoui, Jessica Ohana, Lylia Mekzine, Mona Bensalah, Ngoc Dong Pham Phan, Gillian Butler-Browne, Elisa Negroni, Capucine Trollet, Vincent Mouly
• 2.106P – Dystrophin controls clathrin-mediated endocytosis and endolysosomal homeostasis – Eline Lemerle, Simon Giraud, Satish Babu Moparthi, Marion Benoist, Jeanne Lainé, Quentin Miagoux, Kamel Mamchaoui, Beatrice Labella, Teresinha Evangelista, Xavier Nissan, Helge Amthor, Luis Garcia, Stéphane Vassilopoulos
• 2.108P – No evidence of the presence of dystrophin protein in rodent muscle stem cells – Meriem Matouk, Adrien Morin, Gaspard Macaux, Brendan Evano, Pascal Maire, Vincent Mirouse, Sestina Falcone, Helge Amthor
• 2.123P – Collagen VI is a fibrosis-associated signal disrupting muscle regeneration across distinct human myopathies – Elisa Melissa Negroni, Laura Muraine, Mona Bensalah, Stephen Gargan, Paul Dowling, Anne Bigot, Valérie Allamand, Jamila Dhiab, Maria Kondili, Sophie Perié, Jean Lacau St-Guily, Gillian Butler-Browne, Vincent Mouly, Kay Ohlendieck, Capucine Trollet
• 2.88eP – PHARMA solidaires, a circular social model for medical devices and parapharmaceutical redistribution : five-year sustainability data – Sami Tayb-Boulahfa, Catherine Genton, Solène Emedy, Guillaume Hébert, Aurélie Deltombe, Aurélie Mayeux, Julia Aubé, Aline Lazberg

Friday 2 October 2026 

➢ Poster Sessions

• 3.10P – FLNC-related myopathy: a description of 27 unrelated patients from 26 families – Manh-Louis Nguyen, Beatrice Labella, Teresinha Evangelista, Nathalie Streichenberger, Gisèle Bonne, Pascale Richard, Karim Wahbi, Philippe Petiot, Beatrice Lannes, Aleksandra Nadaj-Pakleza, Marie-Laure Martin-Négrier, Guilhem Sole, Pascale Marcorelles, Yann Pereon, Jean Baptiste Noury, Thierry Maisonobe, Corinne Métay, Anthony Béhin, Tanya Stojkovic
• 3.12P – Engineering 3D human skeletal muscle models to explore fibrosis in the oculopharyngeal muscular dystrophy – Maria Bergas Buades, Laura Muraine, Mona Bensalah, Jessica Ohana, Kamel Mamchaoui, Valentine Hanique, Nami Altin, Penney Gilbert, Stéphanie Descroix, Giacomo Gropplero, Jean Lacau St-Guily, Gillian Butler-Browne, Vincent Mouly, Anne Bigot, Capucine Trollet, Elisa Negroni
• 3.09eP – Spatial dynamics between resident immune cells involve an IFN- and IL15 axis in immune checkpoint blockade-induced muscle toxicity – Julian Sanchez-Dal Cin, Céline Anquetil, Sarah Léonard-Louis, Joe-Elie Salem, Damien Amelin, Bérénice Tendrel, Aude Rigolet, Nicolas Champtiaux, Pascale Daniel, Nadege Wesner, Michelle Rosenzwajg, Fathia Mami-Chouaib, Olivier Benveniste, Stéphanie Corgnac, Yves Allenbach
• 3.13P – Metagenomics for pathogen identification in inflammatory myopathies: a prospective observational study – Yves Allenbach, Andrei-Valentin Brîncuș, Cécile Angebault, Nadège Wesner, Sarah Leonard-Louis, Alexandre Le Joncour, Camille Blandin, Pascal Richette, Philippe Poirier, Olivier Benveniste, Christophe Rodriguez, Françoise Botterel
• 3.30eP – Imaging mass cytometry reveals spatial signatures distinguishing FSHD1 and FSHD2 despite shared clinico-pathological profiles – Bruna Moreira de Souza Proença, Sarah Léonard-Louis, Julian Dal Cin, Bérénice Tendrel, Béatrice Labella, Marion Masingue, Anthony Behin, Frédéric Fer, Édouard Berling, Teresinha Evangelista, Yves Allenbach, Tanya Stojkovic, Olivier Benveniste
• 3.47P – Integrated clinico-histological, transcriptomic, and spatial proteomic characterization of FSHD1 and FSHD2: a monocentric cohort study – Bruna Moreira de Souza Proença, Sarah Léonard-Louis, Julian Dal Cin, Bérénice Tendrel, Béatrice Labella, Marion Masingue, Anthony Behin, Frédéric Fer, Édouard Berling, Teresinha Evangelista, Yves Allenbach, Tanya Stojkovic, Olivier Benveniste
• 3.43eP – Divergent functional trajectories in inclusion body myositis: sirolimus, methotrexate, and untreated patients across two countries – Bruna Moreira de Souza Proença, André Macedo Serafim da Silva, Edmar Zanoteli, Olivier Benveniste
• 3.44eP – Spatial transcriptomics in immune-mediated necrotizing myopathy reveals a specific necrotic signature related to immune-driven fibrosis – Julian Sanchez-Dal Cin, Alexandrine Mahoudeau, Mona Bensalah, Laura Muraine, Bérénice Tendrel, Céline Anquetil, Damien Amelin, Loïs Bolko, Linda Chenane, Franck Letourneur, Angéline Madelaine, Sarah Léonard-Louis, Elisa Negroni, Capucine Trollet, Olivier Benveniste, Yves Allenbach
• 3.68P – Long-term follow-up and risk factors for relapse in patients with anti-HMGCR necrotizing myopathy – Orane Demuynck, Olivier Benveniste
• 3.73P – Development and validation of the MDA-FI score: a simple prognostic tool at diagnosis in anti–MDA5 dermatomyositis – Quentin Astouati, Valentine Pagis, Lucas Pacoureau, Yann Nguyen, Pierre Bay, Antoine Roux, Hubert De Boysson, Laure Gallay, Vincent Cottin, Benjamin Terrier, Alain Meyer, Charles Cerf, Mathilde Neuville, Baptiste Hervier, Hilario Nunes, Eric Hachulla, David Launay, Yurdagül Uzunhan, Olivier Benveniste, Yves Allenbach
• 3.76P – Clinical characteristics and cancer risk of anti-OJ antisynthetase syndrome: a cohort comparative study and a systematic literature review – Yves Allenbach, Valentin Pillot, Segolene Tocquet, Jean Luc Charuel, Sarah Tansley, Samia Boussouar, Pierre Yves Brillet, Hui Lu, Dylan Vellas, Sami Tayb Boulahfa, Sarah Leonard Louis, Yurdagul Uzunhan, Pascale Ghillani-Dalbin, Makoto Miyara, Loïc Baudelet, Maxime Ilzkovitz, Carole Nagant, Anne Marie Bouvier, Valerie Jooste, Olivier Benveniste 
• 3.96P – Mortality and causes of death in idiopathic inflammatory myopathies: survival study from a nationwide French cohort of 2727 patients – Dylan Vellas, Cyril Gitiaux, Ludivine Kouton, Olivier Benveniste, Anne-Sophie Jannot, Yves Allenbach

➢ Short Oral Presentations 7: Congenital muscle diseases 

• SP30 – Defective DNAmacromolécule complexe, l’ADN est le support de l’hérédité (gènes). C’est le constituant des chromosomes. L’ADN est organisé en double hélice (deux brins complémentaires) et constitué de nucléotides de quatre types : adénine, guanine, cytosine et thymine. double-strand break repair through the non-homologous end joining in LMNA-related congenital muscular dystrophy primary myotubes – Marine Leconte, Lucas Ratelet, Zoheir Guesmia, Gisèle Bonne, Anne Bertrand

➢ Short Oral Presentations 8: Myotonic dystrophy therapies 

• SP32 – Tricyclo-DNA antisense oligonucleotide compounds to tackle toxic CUGexp-RNA in a mouse model of myotonic dystrophy type 1 – Julie Fagioli, Cyriaque Beley, Marine Goeffroy, Geneviève Gourdon, Luis Garcia, Denis Furling, Arnaud F. Klein
• SP34 – AAV-based gene therapy for myotonic dystrophy – Ludovic Arandel, Aurelien Cordier, Krizia Ronquillo, Samia Martine, Gilles Moulay, Alain Sureau, Antoine Muchir, Michael Blaser, Nathalie Daniele, Isabelle Richard, Arnaud Klein, Denis Furling 

➢ Poster Sessions

• 4.18P – Human 3D engineered muscle models of X linked myotubular myopathy enable spatiotemporal dissection of core pathological processes – Valentina Maria Lionello, Lucia Rossi, Leah Zerlin, Daniel Moore, Mariam Zouhair, Owen Li Cheuk Kwan, Eugenia Carraro, Rocco D’Antuono, Kamel Mamchaoui, Anne Bigot, Francesco Muntoni, Andrea Serio, Francesco Saverio Tedesco
• 4.45eP – Developing a disease progression model for individuals living with myotonic dystrophy type 1 – Guillaume Bassez, Valeria A Sansone, Benedikt Schoser, Nicholas E Johnson
• 4.68P – Hypokalemic periodic paralysis meets panhypopituitarism: a novel phenotype – Paula Panos-Basterra, Oceana Vieira Pinto-Delaville, Guillaume Taieb, Jean Baptiste Noury, Damien Sternberg, Christel Jublanc, Rocio Nur Villar-Quiles, Savine Vicart
• 4.71P – Exclusion, deficit framing, and reduced patient agency in disability-related sexual health research: a triple burden revealed by a computational analysis – Audrey El Kaim, Frederic Fer, Jean-Yves Hogrel, Marcela Gargiulo
• 4.77P – Tracking disease in motion: wearable-derived insights in neuromuscular disorders – Jean-yves Hogrel, Thomas Marques, Pauline Santmarty, Valérie Decostre, Robert Muni-Lofra, Volker Straub, The DT4RD Consortium
• 4.80P – Toward accessible gait assessment: validity and reliability of a monocular markerless approach in neuromuscular diseases – Pauline Santmarty, Thomas Marques, Frédéric Fer, Guillaume Bassez, Jean-Yves Hogrel, Coralie Bertrand, Hélène Pillet, Laurent Gajny, Romain Feigean

Saturday 3 October 2026 

➢ Victor Dubowitz Lecture

• 15INV – My journey around the nuclear envelope – Gisèle BonneFrance 

➢ Virtual Posters 

• 4.03VP – Patient reality vs scientific priorities in DM1: a multi-source comparative study using the French DM- scope registry – Melinda Gyenge, Manon Brechenmacher, Frédéric Fer, Dalil Hamroun, Gauillaume Bassez, French Filnemus Myotonic Dystrophy Study Group